MedTrace Logo

Fluoxetine to Prevent Relapse and Enhance Psychological Recovery in Women With Anorexia Nervosa

NCT00288574 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 93

Last updated 2017-12-13

Study results available
· View outcomes & findings →

Summary

This study will evaluate the effectiveness of fluoxetine versus placebo in reducing the rate of relapse of anorexia nervosa (AN) and enhancing the psychosocial and behavioral recovery of people who have been treated for AN.

Conditions

Interventions

DRUG

Fluoxetine

DRUG

Placebo

Sponsors & Collaborators

  • National Institute of Mental Health (NIMH)

    collaborator NIH

  • New York State Psychiatric Institute

    lead OTHER

Principal Investigators

  • B. Timothy Walsh, MD · New York State Psychiatric Institute/Columbia University Medical Center

  • Allan Kaplan, MD · Toronto General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-01-31
Primary Completion
2005-05-31
Completion
2005-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00288574 on ClinicalTrials.gov